JOHNSON & JOHNSON: Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients · Ereignisanalyse & Evidenz

BoerseAI

JOHNSON & JOHNSON: Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients · Ereignisanalyse & Evidenz · BoerseAI

Ereignis wird geladen …